

Precipio, Inc. (PRPO)

Nasdaq; business equipment; SIC 3826, Laboratory Analytical Instruments; CIK 0001043961

Precipio, Inc. PRPO; business equipment	
Grade	D/E A B C D E on the D/E boundary of 497 graded peers percentile 80.6; sampling error 2.2 points; lower is stronger
Rank	401 of 497
Profitability	C/D percentile 61.9
Solvency	D percentile 72.0
Growth and financing	C percentile 51.2
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$21.3M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Mar 30, 2026 193 days before the rescans; latest periodic filing 10-Q received Aug 14, 2026
Last close	\$23.15 2026-10-08; market equity \$41.4M
Price used in grade	None



D/E, the sloth
on the D/E boundary of its sector; letters are fifths of the 497 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Apr 21, 2019, D from Apr 21, 2020, E from Apr 21, 2021

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. We aim to achieve this through a combination of clinical laboratory services and proprietary diagnostic product development.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 61.9						
Gross profitability		50.2%	28.5%	16.3	558	2025-12-31
Return on invested capital		(10.4%)	10.9%	86.7	136	2025-12-31
Accruals ratio		(5.5%)	(7.4%)	62.4	621	2025-12-31
Gross margin stability, five years		7.4 pts	2.4 pts	82.2	429	2025-12-31
Solvency, sleeve percentile 72.0						
Twelve-month failure probability		not computable	0.05%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(13.13)	2.18	83.7	566	2025-12-31
Net debt to EBITDA		not computable	1.11x			EBITDA must exceed \$100,000
Interest coverage		not computable	3.77x			one or more required annual facts are missing
Current ratio		1.61x	2.02x	60.3	666	2025-12-31
Growth and financing, sleeve percentile 51.2						
Revenue growth, three-year compound		35.2%	6.4%	7.6	538	2025-12-31
Free cash flow growth, three-year compound		not computable	17.2%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	14.3%			NOPAT must exceed \$100,000
Asset growth, three years		(0.3%)	5.0%	62.1	563	2025-12-31
Net share issuance, one year		18.6%	0.5%	83.7	407	2026-03-23


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 2,568,000 USD; Altman Z is not used

Among 497 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
396	GoDaddy Inc. (GDDY)	79.6	D/E	
397	Blend Labs, Inc. (BLND)	79.8	D/E	fortress balance sheet
398	Trimble Inc. (TRMB)	80.0	D/E	late filer
399	Quanterix Corp. (QTRX)	80.2	D/E	late filer, fortress balance sheet
400	ZoomInfo Technologies Inc. (GTM)	80.4	D/E	
401	Precipio, Inc. (PRPO) <	80.6	D/E	fortress balance sheet
402	Definitive Healthcare Corp. (DH)	80.8	D/E	fortress balance sheet
403	FiEE, Inc. (FIEE)	81.0	D/E	late filer
404	Array Technologies, Inc. (ARRY)	81.2	D/E	
405	Dragonfly Energy Holdings Corp. (DFLI)	81.6	D/E	short runway, late filer
406	Dragonfly Energy Holdings Corp. (DFLIW)	81.6	D/E	short runway, late filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	55.6%	2.2%	82
Distance from 52-week high	(28.4%)	(30.0%)	52
EBIT to enterprise value	(3.1%)	1.5%	23
Free cash flow yield	0.9%	2.7%	31
Book value to price	0.36	0.23	61
Sales to price	0.58	0.30	66
Composite equity issuance, five years	68.0%	3.9%	89
Relative strength against the sector, log excess return	0.16	(0.26)	82

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass

Cash, filings, liquidity	
Cash and equivalents	\$3.1M
Operating cash flow, four quarters	\$1.1M
Months of runway	not finite
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$2.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$10.7M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
2	assets	us-gaap:Assets	\$21.3M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
3	operating income	us-gaap:OperatingIncomeLoss	-\$1.2M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$685,000	2025-12-31	2026-03-30	10-K	0001104659-26-036878
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-30	10-K	0001104659-26-036878
6	total debt	us-gaap:LongTermDebt	\$83,000	2025-12-31	2026-03-30	10-K	0001104659-26-036878
7	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	\$14.6M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$2.7M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
9	total debt	us-gaap:LongTermDebt	\$383,000	2024-12-31	2025-03-27	10-K	0001558370-25-003817
10	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	\$14.6M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.4M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
12	net income	us-gaap:NetIncomeLoss	-\$363,000	2025-12-31	2026-03-30	10-K	0001104659-26-036878
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$685,000	2025-12-31	2026-03-30	10-K	0001104659-26-036878
14	assets	us-gaap:Assets	\$17.0M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$24.2M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
16	gross profit	us-gaap:GrossProfit	\$7.6M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$18.6M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
18	gross profit	us-gaap:GrossProfit	\$6.0M	2023-12-31	2025-03-27	10-K	0001558370-25-003817
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.4M	2023-12-31	2025-03-27	10-K	0001558370-25-003817
20	gross profit	us-gaap:GrossProfit	\$2.5M	2022-12-31	2024-03-29	10-K	0001558370-24-004365
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.8M	2022-12-31	2024-03-29	10-K	0001558370-24-004365
22	gross profit	us-gaap:GrossProfit	\$2.4M	2021-12-31	2023-03-30	10-K	0001558370-23-005076
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$8.7M	2021-12-31	2023-03-30	10-K	0001558370-23-005076
24	current assets	us-gaap:AssetsCurrent	\$6.0M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
25	current liabilities	us-gaap:LiabilitiesCurrent	\$3.8M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$102.8M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
27	liabilities	us-gaap:Liabilities	\$6.8M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.2M	2025-12-31	2026-03-30	10-K	0001104659-26-036878
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$326,000	2025-12-31	2026-03-30	10-K	0001104659-26-036878
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$439,000	2024-12-31	2026-03-30	10-K	0001104659-26-036878
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$223,000	2024-12-31	2026-03-30	10-K	0001104659-26-036878
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.6M	2023-12-31	2025-03-27	10-K	0001558370-25-003817
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$126,000	2023-12-31	2025-03-27	10-K	0001558370-25-003817
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$7.7M	2022-12-31	2024-03-29	10-K	0001558370-24-004365
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$277,000	2022-12-31	2024-03-29	10-K	0001558370-24-004365
36	current assets	us-gaap:AssetsCurrent	\$3.5M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
37	current liabilities	us-gaap:LiabilitiesCurrent	\$4.3M	2024-12-31	2026-03-30	10-K	0001104659-26-036878
38	assets	us-gaap:Assets	\$18.1M	2023-12-31	2025-03-27	10-K	0001558370-25-003817
39	assets	us-gaap:Assets	\$21.5M	2022-12-31	2024-03-29	10-K	0001558370-24-004365
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,783,682	2026-03-23	2026-03-30	10-K	0001104659-26-036878
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,504,312	2025-03-24	2025-03-27	10-K	0001558370-25-003817